Global Treatment Resistant Depression Market, by Drug Type (Antidepressants (Selective Serotonin Reuptake Inhibitors, Serotonin-norepinephrine Reuptake Inhibitors, and Others) Atypical agents, others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 1,180.0 Mn in 2022 and is expected to exhibit a CAGR of 3.4% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
The increasing prevalence of depression is expected to drive growth of global treatment resistant depression market over the forecast period. For instance, according to the an article by the Journal of Clinical Psychiatry in 2021, the estimated 12-month prevalence for 2017, of medication-treated major depressive disorder (MDD) in the U.S. was 8.9 million adults, and 2.8 million (30.9%) had treatment-resistant depression
Global Treatment Resistant Depression Market – Impact of Coronavirus (COVID-19) Pandemic
The most recent pandemic is the coronavirus (COVID-19) pandemic, which was initially detected on December 31, 2019, in Wuhan, China. COVID-19 was declared a pandemic by the World Health Organization on March 11, 2020. According to the World Health Organization's Coronavirus Illness (COVID-19) Epidemiological Update, coronavirus disease (COVID-19) caused approximately 532 million cases and 6 million fatalities globally, till June 6, 2022.
The COVID-19 pandemic affected the ongoing clinical trial studies on drugs for depression by various research institutes which had a negative impact on research and development activities for new drugs development globally. For instance, on April 23, 2020, Medidata technology and solutions, a global platform that supports clinical trials, performed an electronic (video conference) survey of 9,952 staff at various trial investigator sites, globally. The survey had a low response rate of 10.3%, as only few respondents answered the survey in a total of 1,030 participants. Most of the respondents in the survey were from the U.S. (North America; 58.3%), followed by Asia Pacific (23.8%), Europe (8.1%), South & Central America (7.1%), and Middle East & Africa (2.7%). The respondents included in the study were study coordinators, investigators, site managers/directors, clinical nurses, and others. The survey results showed that the ability to conduct ongoing clinical trials during the COVID-19 pandemic had affected the initiation of new trials.
Browse 40 Market Data Tables and 48 Figures spread through 197 Pages and in-depth TOC on “Global Treatment Resistant Depression Market”- Global Forecast to 2030, Global Treatment Resistant Depression Market, by Drug Type (Antidepressants (Selective Serotonin Reuptake Inhibitors, Serotonin-norepinephrine Reuptake Inhibitors, and Others) Atypical agents, others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/treatment-resistant-depression-market-5196
Moreover, increasing number of generic product launches by key market players is expected to drive growth of global treatment resistant depression market over the forecast period. For instance, in September 2019, Dr. Reddy’s Laboratories Ltd. announced the launch of Bupropion Hydrochloride Extended-Release Tablets, USP (SR), a therapeutically equivalent generic version of Zyban (Bupropion Hydrochloride) Extended-Release Tablets, approved by the U.S. Food and Drug Administration (US FDA).
Key Takeaways of the Global Treatment Resistant Depression Market:
- Global treatment resistant depression market is expected to exhibit a CAGR of 3.4% during the forecast period, owing to the increasing prevalence of treatment-resistant depression is expected to drive the market growth in the region over the forecast period. For instance, according to an article published by Frontiers Media S.A. in 2 March 2022, the regional prevalence of treatment-resistant depression (TRD) among major depressive disorder (MDD) patients was as follows: 21% in Mexico, 32% in Colombia, 33% in Argentina, and 40% in Brazil.
- Major players operating in the global treatment resistant depression market include AbbVie Inc., Lupin, Eli Lilly and Company, GlaxoSmithKline Plc., Pfizer Inc., Bausch Health Companies Inc., Sanofi, Mallinckrodt, Johnson & Johnson, Merck & Co., Inc., Viatris Inc., Otsuka Holdings Co., Ltd., H. Lundbeck A/S, AstraZeneca, and Aurobindo Pharma Ltd.
